VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer

Brian Nussenbaum, MD
Published: Wednesday, Aug 10, 2016


Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

Patients who should be considered for such surgeries are those in which a partial laryngectomy would be an oncologically sound operation. Surgeons should also be confident in achieving a negative margin of resection, so that the positive margin rates would be very low. The surgery would also lead to good functional outcomes for patients, Nussenbaum adds.

Additional patients to consider are those with a preference to have organ preservation alone versus combined with radiation and/or chemoradiation. Thirdly, organ preservation surgery may be the only necessary, and potentially curative, treatment for select patients.

Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

Patients who should be considered for such surgeries are those in which a partial laryngectomy would be an oncologically sound operation. Surgeons should also be confident in achieving a negative margin of resection, so that the positive margin rates would be very low. The surgery would also lead to good functional outcomes for patients, Nussenbaum adds.

Additional patients to consider are those with a preference to have organ preservation alone versus combined with radiation and/or chemoradiation. Thirdly, organ preservation surgery may be the only necessary, and potentially curative, treatment for select patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x